drug summary · 2 NDC codes
Kalydeco 50 mg/1
ivacaftor
HUMAN PRESCRIPTION DRUG record from the RxAtlas dataset, marketing status NDA. Facts and NDC codes below are exported values from the current release, not inferred or edited prose.
Facts
Field definitions, types, and provenance rules are in the data dictionary.
| generic name | ivacaftor |
|---|---|
| active ingredients | IVACAFTOR |
| dosage form | GRANULE |
| route | ORAL |
| strength | 50 mg/1 |
| marketing status | NDA |
| DEA schedule | not reported |
| application number | NDA207925 |
| ATC code | not reported |
| RxCUI | not reported |
| manufacturer | Vertex Pharmaceuticals Incorporated |
| product type | HUMAN PRESCRIPTION DRUG |
| pharmacologic class | Chloride Channel Activation Potentiators [MoA]; Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]; Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 3A Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA] |
NDC codes
2 National Drug Codes are mapped to this product in the current release. Package descriptions are not part of the published export, so the NDC code is the canonical package identifier here.
| NDC | Package description |
|---|---|
| 51167-300 | — |
| 51167030001 | — |
Other ivacaftor products
5 other products in the current release publish the same generic name. Strength, dosage form, and labeler are what distinguish them.
- Kalydeco 13.4 mg/1GRANULE · Vertex Pharmaceuticals Incorporated
- Kalydeco 150 mg/1TABLET, FILM COATED · Vertex Pharmaceuticals Incorporated
- Kalydeco 25 mg/1GRANULE · Vertex Pharmaceuticals Incorporated
- Kalydeco 5.8 mg/1GRANULE · Vertex Pharmaceuticals Incorporated
- Kalydeco 75 mg/1GRANULE · Vertex Pharmaceuticals Incorporated
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access to the full catalogue; credited toward the licence.